Leickert, Jule
Zillmer, Stephan
Bachmann, Christian J.
Vivirito, Annika
Enders, Dirk
Pintsch, Josephine
Correll, Christoph U.
Jaite, Charlotte
Funding for this research was provided by:
Universität Hildesheim
Article History
Received: 30 October 2024
Accepted: 5 March 2025
First Online: 21 March 2025
Declarations
:
: Due to anonymization of the claims data within the InGef Berlin GmbH database (secondary data) ethics approval for this study was not required. No individuals, statutory health insurance companies or health care service providers can be identified. InGef provided the anonymised secondary data required for the project and has the necessary authorisations to use the data from the participating health insurance and the competent authorities. The study was conducted according to the following national and international guidelines: Good Practice of Secondary Data Analysis, Good epidemiological practice, Guidelines for Good Pharmacoepidemiology Practice, ENCePP-Guidelines for Methodological Standards in Pharmacoepidemiology.
: Not applicable.
: C.U. Correll has served as consultant/advisor or received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, Terran.